#DNTH↓

DNTH/ 03/09/2026 · 9:19 AM

Dianthus Therapeutics Scores Early Phase 3 Win in CIDP: Claseprubart Hits GO Decision Ahead of Schedule

Dianthus shares surged after an early “GO” decision in Phase 3 CAPTIVATE trial of claseprubart for CIDP. Strong 50%+ response rate and clean safety profile reported. Top-line data expected by end of 2026.

DNTH/ 09/08/2025 · 8:23 AM

Dianthus Therapeutics: Myasthenia Gravis Drug Shows Promise

Dianthus's Claseprubart shows promising Phase 2 results for gMG, significantly improving daily activities & muscle strength with good safety. Plans for a convenient self-administered dose and a Phase 3 trial in 2026.